Canada markets open in 8 hours 51 minutes
  • S&P/TSX

    18,881.19
    +436.97 (+2.37%)
     
  • S&P 500

    3,678.43
    +92.81 (+2.59%)
     
  • DOW

    29,490.89
    +765.38 (+2.66%)
     
  • CAD/USD

    0.7353
    +0.0011 (+0.15%)
     
  • CRUDE OIL

    83.82
    +0.19 (+0.23%)
     
  • BTC-CAD

    26,658.88
    +506.81 (+1.94%)
     
  • CMC Crypto 200

    445.95
    +10.60 (+2.43%)
     
  • GOLD FUTURES

    1,708.10
    +6.10 (+0.36%)
     
  • RUSSELL 2000

    1,708.87
    +44.15 (+2.65%)
     
  • 10-Yr Bond

    3.6510
    0.0000 (0.00%)
     
  • NASDAQ futures

    11,396.25
    +110.50 (+0.98%)
     
  • VOLATILITY

    30.10
    -1.52 (-4.81%)
     
  • FTSE

    6,908.76
    +14.95 (+0.22%)
     
  • NIKKEI 225

    26,958.59
    +742.80 (+2.83%)
     
  • CAD/EUR

    0.7472
    +0.0004 (+0.05%)
     

Is Aptose Biosciences (TSE:APS) In A Good Position To Invest In Growth?

·4 min read

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

Given this risk, we thought we'd take a look at whether Aptose Biosciences (TSE:APS) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

See our latest analysis for Aptose Biosciences

Does Aptose Biosciences Have A Long Cash Runway?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. When Aptose Biosciences last reported its balance sheet in March 2022, it had zero debt and cash worth US$70m. In the last year, its cash burn was US$43m. Therefore, from March 2022 it had roughly 20 months of cash runway. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces drastically. The image below shows how its cash balance has been changing over the last few years.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Aptose Biosciences' Cash Burn Changing Over Time?

Because Aptose Biosciences isn't currently generating revenue, we consider it an early-stage business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. With the cash burn rate up 18% in the last year, it seems that the company is ratcheting up investment in the business over time. However, the company's true cash runway will therefore be shorter than suggested above, if spending continues to increase. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Hard Would It Be For Aptose Biosciences To Raise More Cash For Growth?

Given its cash burn trajectory, Aptose Biosciences shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Aptose Biosciences has a market capitalisation of US$72m and burnt through US$43m last year, which is 59% of the company's market value. That's high expenditure relative to the value of the entire company, so if it does have to issue shares to fund more growth, that could end up really hurting shareholders returns (through significant dilution).

So, Should We Worry About Aptose Biosciences' Cash Burn?

On this analysis of Aptose Biosciences' cash burn, we think its cash runway was reassuring, while its cash burn relative to its market cap has us a bit worried. Looking at the factors mentioned in this short report, we do think that its cash burn is a bit risky, and it does make us slightly nervous about the stock. Taking a deeper dive, we've spotted 5 warning signs for Aptose Biosciences you should be aware of, and 2 of them are a bit unpleasant.

Of course Aptose Biosciences may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here